NASDAQ$APGE
Apogee Therapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Apogee reported fourth quarter and full year 2025 results, reflecting continued operating losses as it advanced its clinical-stage pipeline.
For the quarter ended December 31, 2025, Apogee reported a net loss of 255843000 and an operating loss of 285595000, driven by research and development expenses of 214712000 and general and administrative expenses of 70883000. The company ended the year with 131549000 in cash and cash equivalents.
- Net loss for Q4 2025 was 255843000.
- Operating loss totaled 285595000 for the quarter.
- Research and development expenses were 214712000.
- Cash and cash equivalents were 131549000 at December 31, 2025.
Headline financials
Revenue & EPS history
Apogee · Revenue · Quarterly
$0
Forward guidance
The company expects its existing cash, cash equivalents and marketable securities to fund operations for at least the next 12 months.
Tailwinds
- Cash and cash equivalents of 131549000 at year-end 2025.
- Marketable securities of 598643000 as of December 31, 2025.
- Long-term marketable securities of 172730000.
- Sufficient liquidity projected for at least 12 months.
- Continued advancement of multiple clinical programs.
Headwinds
- Net loss of 255843000 for the quarter.
- Operating loss of 285595000.
- No product revenue generated.
- Accumulated deficit of 561759000 as of December 31, 2025.
- Ongoing dependence on external financing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2025
+5.6%
Avg return
Earnings day
+9.2%
Avg return
5 days after
+10.9%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+59.8%
Q4 2023
Best reaction
-12.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +4.4% | +20.3% | |
| Q3 2025 | +3.8% | +19.7% | +39.0% | |
| Q2 2025 | -2.2% | +5.4% | +5.9% | |
| Q1 2025 | -0.0% | -1.1% | +9.4% | |
| Q4 2024 | -0.2% | +14.9% | +20.3% | |
| Q3 2024 | -12.7% | -21.8% | -26.7% | |
| Q2 2024 | +9.7% | +11.7% | +25.0% | |
| Q1 2023 | +1.5% | -5.5% | -16.7% | |
| Q1 2024 | +1.5% | -5.5% | -16.7% | |
| Q4 2023 | +59.8% | +61.8% | +41.4% | |
| Q3 2023 | +12.8% | +20.6% | +45.9% | |
| Q3 2022 | +12.8% | +20.6% | +45.9% | |
| Q4 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2023 | -1.1% | +4.0% | -9.6% | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro